Steroid Implants and the Pharmacology of Diabetic Retinopathy
Diabetic eye disease is where the retina keeps the score of a systemic illness. Long before a patient notices blurred vision, high sugar has been quietly corroding the smallest vessels at the back of the eye — leaking, then closing, then starving the retina of oxygen. The reflex is to reach for an intravitreal drug, and often that is right. But the deepest truth of this chapter is that the most powerful treatment is not injected into the eye at all: it is good control of glucose, blood pressure and lipids. When drugs are needed, anti-VEGF leads — and for oedema that will not settle, a small sustained-release steroid implant can be planted inside the eye to release medicine for months. That elegance comes at a price the whole of ophthalmology already knows: steroids raise pressure and cloud the lens, and an implant magnifies both.
A 58-year-old man with type 2 diabetes of fifteen years comes to the eye clinic because a fog has crept into the centre of his reading vision. His HbA1c has run high for years, his blood pressure is untreated, and he has not had a retinal screen since diagnosis. On examination the macula is thickened and wet — diabetic macular oedema — and the periphery shows the tell-tale dot-and-blot haemorrhages and cotton-wool spots of ischaemia. He has already had a course of anti-VEGF injections elsewhere with only a partial response, and he struggles to attend monthly appointments. He is also pseudophakic — he had cataract surgery two years ago. Standing at this crossroads, the ophthalmologist is weighing a sustained-release steroid implant: one that could dry the macula for months without the treadmill of monthly visits. But the first sentence of the consultation is not about the eye at all — it is about his sugar, his pressure and his lipids.
What high sugar does to the retina
Diabetic retinopathy is, at heart, a disease of the smallest blood vessels. Chronic hyperglycaemia damages the microvasculature of the retina in two linked ways. First, the walls of the capillaries weaken — pericytes are lost, the vessels balloon into microaneurysms, and the blood–retinal barrier that normally keeps fluid inside the vessels breaks down. Fluid and lipid leak into the retina, and when this happens at the macula — the small central patch responsible for sharp vision — the retina swells: diabetic macular oedema, the commonest cause of visual loss in diabetes. Second, over years the capillaries progressively close off. Whole areas of retina lose their blood supply and become ischaemic — starved of oxygen. That ischaemia is the engine that drives the disease forward.
A starved retina does not stay silent. It releases a chemical distress call — chiefly vascular endothelial growth factor (VEGF) — a signal that shouts "grow me new vessels, I need oxygen." VEGF does two harmful things. It makes existing vessels leakier, worsening the macular oedema. And it drives the growth of fragile new vessels (neovascularisation) across the retina and optic disc: proliferative diabetic retinopathy. These new vessels are disorganised and bleed easily, causing vitreous haemorrhage, and they can drag on the retina and detach it. VEGF is therefore both the mediator of the swelling and the trigger of the dangerous proliferative stage — which is exactly why blocking it, covered in the Anti-VEGF chapter, became so transformative.
Think of the retinal circulation as an old irrigation network feeding a precious garden. Years of hard water (high sugar) corrode the pipes: some spring leaks that flood the flowerbeds (macular oedema), while others silt up entirely and leave whole plots parched (ischaemia). The parched ground sends up a chemical flare (VEGF) begging for new pipes — but the new pipes are cheap, leaky and burst easily, flooding and choking the garden further. The gardener has three tools: fix the water supply itself (systemic control), cauterise the dead plots so they stop crying out (laser), or intercept the flare in the air (anti-VEGF). And when the flowerbeds stay flooded despite all that, a slow-drip valve of anti-inflammatory medicine (a steroid implant) can be buried in the soil to keep them dry for months.
The real foundation: treat the diabetes, not just the eye
No intravitreal drug can outrun uncontrolled systemic disease. The single most important intervention in diabetic retinopathy is never delivered by the ophthalmologist. It is tight, sustained control of the systemic drivers: blood glucose above all, but also blood pressure and blood lipids. Landmark diabetes trials showed that lowering HbA1c and blood pressure markedly slows the onset and progression of retinopathy — a benefit that compounds over years. This is why the diabetic patient belongs as much to the Endocrine & Metabolic and Cardiovascular chapters as to ophthalmology: the metformin, GLP-1 agonists, insulin, antihypertensives and statins prescribed by the physician are, in a real sense, retinal drugs. Alongside control sits screening: because early retinopathy is silent, every person with diabetes needs regular dilated retinal examination so that disease is caught before vision is lost.
A famous and counter-intuitive trap: tightening a chronically high blood sugar too rapidly can transiently WORSEN retinopathy — "early worsening" — before the long-term benefit appears. This is well recognised when starting intensive insulin or after bariatric surgery in a patient with long-standing poor control and existing retinopathy. The lesson is not to leave sugar high — control still wins over years — but to check the retina before and during rapid intensification, and to bring the eyes under surveillance rather than be caught off guard. It is a perfect illustration of why the endocrinologist and the ophthalmologist must talk to each other.
- Chronic hyperglycaemia damages retinal capillaries: leakage (breaking the blood–retinal barrier) and closure (ischaemia).
- Ischaemia drives VEGF release, which worsens oedema and triggers fragile new vessels (proliferative disease).
- Diabetic macular oedema — fluid at the fovea — is the commonest cause of visual loss in diabetes.
- The FOUNDATION of treatment is systemic: glycaemia, blood pressure and lipids — plus regular retinal screening.
- Rapid glycaemic tightening can transiently worsen retinopathy before the long-term benefit — monitor the retina.
- Anti-VEGF and laser are the eye-directed mainstays; steroids are a further tool for stubborn oedema.
Laser and anti-VEGF — the eye-directed workhorses
For decades the mainstay was laser photocoagulation, and it still has a defined role. Focal (grid) laser is applied to leaking spots near the macula to seal them. Panretinal photocoagulation (PRP) takes a different, almost paradoxical approach to proliferative disease: the laser deliberately destroys patches of the oxygen-starved peripheral retina. With less ischaemic tissue crying out, VEGF production falls and the dangerous new vessels regress. The cost is peripheral and night vision — you sacrifice the periphery to save central sight. Since the 2010s, however, intravitreal anti-VEGF injections (ranibizumab, aflibercept, bevacizumab, and newer agents such as faricimab and brolucizumab) have moved to first line for both diabetic macular oedema and much proliferative disease. They mop up the VEGF distress signal directly, drying the macula and driving neovascularisation back — often with better visual gains than laser. Their drawback is the burden: injections must be repeated, initially as often as monthly, which is heavy for patients and clinics alike.
Intravitreal corticosteroid implants: a depot inside the eye
When anti-VEGF is not enough, a steroid attacks the oedema from a different angle. Diabetic macular oedema is not driven by VEGF alone — inflammation is a major partner. Corticosteroids act broadly: locally they suppress a whole cascade of inflammatory cytokines, dampen VEGF production, and directly tighten the blood–retinal barrier to reduce vascular permeability. That multi-target action is why a steroid can dry a macula that has responded incompletely to anti-VEGF. The problem historically was delivery — a steroid injected as a bolus washes out in days. The engineering answer is the sustained-release implant: a tiny rod injected into the vitreous that slowly dissolves or elutes drug over months. The dexamethasone implant (Ozurdex) is biodegradable and lasts roughly three to six months. The fluocinolone acetonide implants (Iluvien, and the surgically placed Retisert) release a low dose for far longer — Iluvien for up to about three years. For a patient who cannot attend monthly, or whose oedema keeps recurring, a single implant that works for months is a genuinely different proposition.
The clinical niche is specific. Steroid implants shine in diabetic macular oedema that responds poorly to anti-VEGF, in oedema from retinal vein occlusion, and in non-infectious posterior uveitis — an inflammatory rather than purely diabetic indication where Ozurdex and Retisert are established. Triamcinolone acetonide, an older intravitreal steroid injection, is the cheaper predecessor: effective but short-lived and, as a suspension, more prone to raising eye pressure. The choice between steroid and anti-VEGF is a clinical judgement. Anti-VEGF is usually first because it lacks the steroid's ocular hazards; a steroid is favoured when injections are incomplete or too frequent to sustain, when inflammation dominates, or — importantly — in an eye that has already had its lens removed, for a reason the next section makes clear.
Dexamethasone implant (Ozurdex): biodegradable, ~3–6 months, for DMO, vein-occlusion oedema and posterior uveitis. Fluocinolone acetonide implants — Iluvien (injectable, up to ~3 years, for chronic DMO) and Retisert (surgically implanted, ~2.5 years, for chronic non-infectious posterior uveitis). Triamcinolone acetonide: the older intravitreal injection, short-acting and prone to raising IOP. Across all of them the mechanism is the same — a local anti-inflammatory that suppresses cytokines, VEGF and vascular leak — and so is the signature hazard: raised intraocular pressure and cataract, magnified by sustained delivery, which is why these are often reserved for pseudophakic eyes.
The magnified price: steroid glaucoma and cataract
Every ocular steroid carries two classic hazards; an implant amplifies both. The two enemies of ocular corticosteroids are well known from the general Ocular steroids chapter, and a sustained-release depot is the worst-case exposure for both. First, raised intraocular pressure: steroids reduce the outflow of aqueous through the trabecular meshwork, and in susceptible "steroid responders" the pressure can climb into a glaucomatous range, threatening the optic nerve. With months of continuous drug inside the eye, this is common rather than rare, and it may need pressure-lowering drops or even surgery. Second, cataract: steroids reliably accelerate a posterior subcapsular cataract, clouding the lens. This is why implants are often chosen for pseudophakic eyes — an eye that has already had cataract surgery has an artificial lens that cannot cloud, removing one of the two big risks at a stroke. In a phakic eye, the near-certainty of cataract is a real deterrent. These are precisely the toxicities the Ocular Toxicity chapter details, seen here at their most concentrated.
- Steroid implants work by suppressing inflammatory cytokines, VEGF and vascular permeability locally, tightening the blood–retinal barrier.
- Dexamethasone (Ozurdex) lasts months; fluocinolone (Iluvien/Retisert) lasts years — useful when injection frequency is a burden.
- Best niches: DMO with incomplete anti-VEGF response, vein-occlusion oedema, and non-infectious posterior uveitis.
- Signature hazards: raised IOP/glaucoma and cataract — both common and magnified by sustained release.
- Often reserved for pseudophakic eyes, removing the cataract risk; anti-VEGF stays first line for most DMO.
- Treating the eye while ignoring the systemic disease — no injection outperforms good control of glucose, blood pressure and lipids, plus screening.
- Placing a steroid implant in a phakic eye without warning the patient that cataract is near-certain, and forgetting to monitor intraocular pressure for months afterwards.
- Reassuring a newly intensified diabetic that tighter sugar can only help the eyes — forgetting that rapid tightening can transiently worsen retinopathy, so the retina must be watched.
A 60-year-old pseudophakic man has diabetic macular oedema that has responded only partially to repeated anti-VEGF injections, and he struggles to attend monthly. A dexamethasone (Ozurdex) implant is planned. Which complication should he be counselled about and monitored for most closely?
- Diabetic retinopathy is microvascular damage from chronic hyperglycaemia: leakage breaks the blood–retinal barrier (macular oedema) and ischaemia drives VEGF and new-vessel growth.
- The foundation of treatment is systemic control of glucose, blood pressure and lipids plus screening — no intravitreal drug substitutes for it (and rapid tightening can transiently worsen the retina).
- Eye-directed therapy: laser (focal/panretinal) and, first line, anti-VEGF injections for oedema and proliferative disease.
- Sustained-release corticosteroid implants — dexamethasone (Ozurdex, months) and fluocinolone (Iluvien/Retisert, years) — treat stubborn oedema and posterior uveitis but commonly cause raised IOP and cataract, so are often used in pseudophakic eyes.
- Kanski's Clinical Ophthalmology: A Systematic Approach — Diabetic retinopathy and diabetic macular oedema.
- American Academy of Ophthalmology, Basic and Clinical Science Course (BCSC) — Retina and Vitreous.
- Bartlett & Jaanus, Clinical Ocular Pharmacology — Corticosteroids and posterior-segment drug delivery.
- Royal College of Ophthalmologists / NICE guidance — Diabetic retinopathy and diabetic macular oedema management.
- Diabetes Control and Complications Trial (DCCT) and UK Prospective Diabetes Study (UKPDS) — glycaemic and blood-pressure control and retinopathy.
- Rang & Dale's Pharmacology / Katzung Basic & Clinical Pharmacology — Corticosteroids and antidiabetic drugs.
